

ardous. In our view, awareness of this phenomenon, together with advanced planning, is critical in successfully securing the airway in these patients.

## References

1. Mulliken JB, Glowacki J: Hemangiomas and vascular malformations in infants and children: A classification based on endothelial characteristics. *Plast Reconstr Surg* 1982; 69:412-22

2. Dubois JM, Sebag GH, De PY, Teillac D, Chretien B, Brunelle FO: Soft-tissue venous malformations in children: Percutaneous sclerotherapy with Ethibloc. *Radiology* 1991; 180:195-8

3. Shiga T, Wajima Z, Inoue T, Sakamoto A: Predicting difficult intubation in apparently normal patients: A meta-analysis of bedside screening test performance. *ANESTHESIOLOGY* 2005; 103:429-37

4. Peterson GN, Domino KB, Caplan RA, Posner KL, Lee LA, Cheney FW: Management of the difficult airway: A closed claims analysis. *ANESTHESIOLOGY* 2005; 103:33-9

5. Kheterpal S, Han R, Tremper KK, Shanks A, Tait AR, O'Reilly M, Ludwig TA: Incidence and predictors of difficult and impossible mask ventilation. *ANESTHESIOLOGY* 2006; 105:885-91

Anesthesiology 2007; 107:166-7

Copyright © 2007, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

# Successful Use of Terlipressin in Post-Cardiac Arrest Resuscitation after an Epinephrine-resistant Anaphylactic Shock to Suxamethonium

Nicolas Rocq, M.D.,\* Jean-Christophe Favier, M.D., Ph.D.,† David Plancade, M.D.,‡ Thierry Steiner, M.D.,‡ Paul-Michel Mertes, M.D., Ph.D.§

EPINEPHRINE is considered in most guidelines as the first-line treatment of anaphylactic shock occurring during anesthesia. In some cases, epinephrine is not effective, and alternative therapies have been proposed, such as norepinephrine or metaraminol<sup>1</sup> or, more recently, arginine vasopressin.<sup>2-4</sup> To our knowledge, we are the first to report the successful treatment of anaphylactic shock with terlipressin, a structural analog of arginine vasopressin.

## Case Report

A 47-yr-old male patient was scheduled to undergo elective inguinal hernia repair. This patient was a current smoker (30 pack-years) with a history of gastroesophageal reflux disease and of four uneventful general anesthetics. One hour before surgery, hydroxyzine (1.5 mg/kg) and effervescent cimetidine (400 mg) were administered orally for premedication.

General anesthesia was induced using a target-controlled infusion with propofol (Diprivan®; AstraZeneca, Rueil-Malmaison, France) and remifentanyl (Ultiva®; GlaxoSmithKline, Marly-le-Roi, France), and 1 mg/kg succinylcholine (Celocurine®; Pfizer, Paris, France). After intubation with an 8-mm-ID endotracheal tube (Mallinckrodt Medical, Athlone, Ireland), the patient was ventilated using an anesthesia ventilator (Felix®; Taema, Antony, France).

Four minutes after succinylcholine injection, a severe bronchospasm was observed in the absence of any skin manifestation. Cardiac arrest followed 30 s later. Chest compressions, pure oxygen (fraction of

inspired oxygen = 1) ventilation, discontinuation of sedation agents, and fluid resuscitation (1 l lactated Ringer's solution) were immediately started. A bolus of 1 mg intravenous epinephrine was administered. Recurrent ventricular fibrillations were treated by four electric shocks and amiodarone administration (300 mg over 15 min). Because of hemodynamic instability, continuous epinephrine infusion was rapidly started at increasing doses (1-15 mg/h). Although epinephrine was rapidly efficient on bronchospasm, it did not restore blood pressure (systolic blood pressure 60 mmHg). After 45 min of resuscitation, an echocardiogram showed a hypokinetic left ventricle. Then, a 2-mg bolus of terlipressin (Glypressine®; Ferring SAS, Gentilly, France) was administered, allowing for hemodynamic parameters stabilization (heart rate 80 beats/min, systolic blood pressure 90 mmHg) and a rapid epinephrine weaning (15 mg/h down to 0 mg/h in 30 min).

Blood samples taken less than an hour after the onset of symptoms showed elevated serum tryptase (> 200 µg/l, normal when < 13.5 µg/l) and plasma histamine (> 100 nm, normal when < 10 nm). Anaphylaxis to succinylcholine was confirmed using a specific immunoglobulin (Ig) E radioimmunoassay with an inhibition step<sup>5</sup> (quaternary ammonium ion IgE 19.93% [positivity > 2.0] with a 54.49% inhibition by succinylcholine).

## Discussion

Anaphylactic reactions occurring during anesthesia remain a potentially life-threatening event, with an estimated incidence ranging between 1 in 10,000 and 1 in 20,000 anesthetics.<sup>6</sup> Neuromuscular blocking agents are responsible for more than half of those events, and suxamethonium has been implicated in a majority of cases.<sup>7</sup> However, diagnosis of anaphylaxis could be difficult in the anesthesia setting because clinical signs are often misleading or nonspecific.<sup>8</sup>

Successful treatment of epinephrine- and/or norepinephrine-resistant anaphylaxis using arginine vasopressin has been recently reported.<sup>2,3</sup> However, unlike its long-acting analog terlipressin, arginine vasopressin is not available in France.

Terlipressin has been successfully used as a second-line vasopressor in various hypotensive situations where sym-

\* Resident, § Professor, Pôle Anesthésie-Réanimation, Centre Hospitalier Universitaire, Nancy, France. † Professor, ‡ Staff Physician, Département Anesthésie Réanimation Urgence, Hôpital d'Instruction des Armées Legouest.

Received from the Département Anesthésie Réanimation Urgence, Hôpital d'Instruction des Armées Legouest, Metz, France. Submitted for publication January 29, 2007. Accepted for publication March 13, 2007. Support was provided solely from institutional and/or departmental sources.

Address correspondence to Dr. Rocq: Pôle Anesthésie Réanimation, Hôpitaux de Brabois-Hôpital d'adultes, 4 rue du Morvan, 54511 Vandœuvre les Nancy Cedex, France. rocq.nicolas@gmail.com. Information on purchasing reprints may be found at www.anesthesiology.org or on the masthead page at the beginning of this issue. ANESTHESIOLOGY's articles are made freely accessible to all readers, for personal use only, 6 months from the cover date of the issue.

pathetic agonists were ineffective (catecholamine-resistant septic shock,<sup>9</sup> hypotension during anesthesia in patients chronically treated with angiotensin-converting enzyme inhibitors<sup>10</sup>). However, in a recent study, Dewachter *et al.*<sup>11</sup> compared epinephrine, arginine vasopressin, and terlipressin in an ovalbumin-sensitized anesthetized anaphylactic shock rat model. Unexpectedly, terlipressin did not change mean arterial blood pressure, regardless of the dose used, whereas epinephrine and AVP increased mean arterial pressure in a dose-dependent fashion.<sup>11</sup> Interspecies variations could explain the differences observed between these experimental results and our clinical case. One should also note that in our case, terlipressin was administered after epinephrine administration, whereas it was administered as a single drug in the previously reported experimental study. Therefore, one could not exclude a beneficial effect of the combination of both drugs.

Our case report underlines the interest of immediate tryptase and specific IgE measurements in case of unexpected cardiac arrest after anesthesia induction. It suggests that adding terlipressin to standard therapy should be considered when epinephrine does not restore vascular tone.

The authors thank Mary Doherty, M.D. (Staff Physician, Mayo General Hospital, Castlebar, Ireland), for reviewing the manuscript.

## References

1. Heytman M, Rainbird A: Use of alpha-agonists for management of anaphylaxis occurring under anaesthesia: Case studies and review. *Anaesthesia* 2004; 59:1210-5
2. Kill C, Wranze E, Wulf H: Successful treatment of severe anaphylactic shock with vasopressin. *Int Arch Allergy Immunol* 2004; 134:260-1
3. Schummer W, Schummer C, Wippermann J, Fuchs J: Anaphylactic shock: Is vasopressin the drug of choice? *ANESTHESIOLOGY* 2004; 101:1025-7
4. Williams SR, Denault AY, Pellerin M, Martineau R: Vasopressin for treatment of shock following aprotinin administration. *Can J Anaesth* 2004; 51:169-72
5. Mertes PM, Laxenaire MC, Alla F: Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. *ANESTHESIOLOGY* 2003; 99: 536-45
6. Laxenaire MC: Epidemiology of anesthetic anaphylactoid reactions: Fourth multicenter survey (July 1994-December 1996) [in French]. *Ann Fr Anesth Reanim* 1999; 18:796-809
7. Mertes PM, Pinaud M: What are the physiopathological mechanisms? How can severe anaphylactoid reactions be explained [in French]. *Ann Fr Anesth Reanim* 2002; 21:55s-72s
8. Jacobsen J, Lindekaer AL, Ostergaard HT, Nielsen K, Ostergaard D, Laub M, Jensen PF, Johannessen N: Management of anaphylactic shock evaluated using a full-scale anaesthesia simulator. *Acta Anaesthesiol Scand* 2001; 45:315-9
9. O'Brien A, Clapp L, Singer M: Terlipressin for norepinephrine-resistant septic shock. *Lancet* 2002; 359:1209-10
10. Eyraud D, Brabant S, Nathalie D, Fleron MH, Gilles G, Bertrand M, Coriat P: Treatment of intraoperative refractory hypotension with terlipressin in patients chronically treated with an antagonist of the renin-angiotensin system. *Anesth Analg* 1999; 88:980-4
11. Dewachter P, Jouan-Hureau V, Lartaud I, Bello G, de Talence N, Longrois D, Mertes PM: Comparison of arginine vasopressin, terlipressin, or epinephrine to correct hypotension in a model of anaphylactic shock in anesthetized brown Norway rats. *ANESTHESIOLOGY* 2006; 104:734-41